Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silvercorp to Acquire Adventus Creating a Diversified Mining Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Ultragenyx Pharmaceutical Inc RARE

Healthcare Biotechnology
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product... see more

Recent & Breaking News (NDAQ:RARE)

Benzinga's Daily Biotech Pulse: Eiger And Melinta Fall On Offerings, Apellis And Marinus Rise On Bullish Ratings

Benzinga.com  May 24, 2018

Ultragenyx and Kyowa Kirin Announce Publication of Phase 2 Study Results Demonstrating that Crysvita® (burosumab) Improved Outcomes in Children with X-linked Hypophosphatemia in the New England Journal of Medicine

GlobeNewswire May 23, 2018

Ultragenyx and Kyowa Kirin Announce Topline Phase 3 Study Results Demonstrating Superiority of Crysvita® (burosumab) Treatment to Oral Phosphate and Active Vitamin D in Children with X-Linked Hypophosphatemia (XLH)

GlobeNewswire May 17, 2018

Ultragenyx Reports First Quarter 2018 Financial Results and Corporate Update

GlobeNewswire May 7, 2018

Ultragenyx Pharmaceutical, Inc. to Host Earnings Call

Accesswire May 7, 2018

Ultragenyx to Host Conference Call for First Quarter 2018 Financial Results and Corporate Update

GlobeNewswire May 1, 2018

Ultragenyx and Kyowa Kirin Announce Crysvita® (burosumab-twza) Now Launched in the U.S. for the Treatment of X–linked Hypophosphatemia (XLH) in Children and Adults

GlobeNewswire April 30, 2018

Ultragenyx and Kyowa Kirin Announce FDA Approval of Crysvita® (burosumab-twza) for the Treatment of Children and Adults with X–Linked Hypophosphatemia (XLH)

GlobeNewswire April 17, 2018

The Week Ahead In Biotech: PDUFA Dates, IPOs And More

Benzinga.com  April 13, 2018

Ultragenyx to Present at Upcoming Investor Conferences

GlobeNewswire March 8, 2018

Ultragenyx Announces Positive Topline Results and DMC Review from First Cohort of Phase 1/2 Clinical Study of DTX301, an Investigational Gene Therapy in Ornithine Transcarbamylase (OTC) Deficiency

GlobeNewswire March 7, 2018

Kyowa Kirin and Ultragenyx Announce Crysvita® (burosumab) Receives Conditional Marketing Authorization in Europe for the Treatment of X–Linked Hypophosphatemia in Children

GlobeNewswire February 23, 2018

Ultragenyx Reports Fourth Quarter and Full Year 2017 Financial Results and Corporate Update

GlobeNewswire February 20, 2018

Ultragenyx Pharmaceutical, Inc. to Host Earnings Call

Accesswire February 20, 2018

Ultragenyx to Present at Leerink Partners Global Healthcare Conference

GlobeNewswire February 8, 2018

Ultragenyx Appoints Camille L. Bedrosian, M.D. as Chief Medical Officer and Executive Vice President

GlobeNewswire January 29, 2018

Ultragenyx Announces Pricing of Public Offering of Common Stock

GlobeNewswire January 23, 2018

Ultragenyx Announces Proposed Public Offering of Common Stock

GlobeNewswire January 22, 2018

Newman Ferrara LLP Announces Corporate Governance Investigation of Ultragenyx Pharmaceutical Inc. - RARE

Business Wire January 8, 2018

Ultragenyx Announces Positive Interim Topline Results From First Cohort of Phase 1/2 Clinical Study of DTX301 Gene Therapy in Ornithine Transcarbamylase (OTC) Deficiency 

GlobeNewswire January 7, 2018